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Abstract
Background: The tachykinins are implicated in neurogenic inflammation and the neuropeptide substance P in particular has
been shown to be a proinflammatory mediator. A role for the tachykinins in host response to lung challenge has been
previously demonstrated but has been focused predominantly on the release of the tachykinins from nerves innervating the
lung. We have previously demonstrated the most dramatic phenotype described for the substance P encoding gene
preprotachykinin-A (PPT-A) to date in controlling the host immune response to the murine gammaherpesvirus 68, in the lung.
Methodology/Principal Findings: In this study we have utilised transgenic mice engineered to co-ordinately express the
beta-galactosidase marker gene along with PPT-A to facilitate the tracking of PPT-A expression. Using a combination of
these mice and conventional immunohistology we now demonstrate that PPT-A gene expression and substance P peptide
are induced in cells of the respiratory tract including tracheal, bronchiolar and alveolar epithelial cells and macrophages
after viral infection. This induction was observed 24h post infection, prior to observable inflammation and the expression of
pro-inflammatory chemokines in this model. Induced expression of the PPT-A gene and peptide persisted in the lower
respiratory tract through day 7 post infection.
Conclusions/Significance: Non-neuronal PPT-A expression early after infection may have important clinical implications for
the progression or management of lung disease or infection aside from the well characterised later involvement of the
tachykinins during the inflammatory response.
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Introduction
The tachykinin family of neurotransmitters are not only
involved in central and peripheral nervous system function but
also have a role in inflammation (termed neurogenic inflamma-
tion) and adaptive immunity [1,2]. The most characterized
member of the family is substance P (SP). This is encoded by
the preprotachykinin A (PPT-A) locus. Alternative splicing of PPT-
A RNA and processing of the propeptide yields, in addition to SP,
neurokinin A (NKA) and neuropeptides K and c. Individual
spliced forms invariably encode SP and a variable combination of
these other peptides. A major physiological source of SP is primary
sensory neurons, whose cell bodies in the dorsal root ganglia
produce SP and transport it to peripheral and central sites where it
is stored and later released from nerve endings. Although local
nerves have been believed to be the major source of tachykinins in
the peripheral tissues, PPT-A has been shown to be induced and
expressed in other cell types such as monocytes, macrophages,
pancreatic islet cells and various tumour cell types [3–7]. This has
led to the hypothesis that SP not only acts as a mediator of the
neuroimmune system but is also involved in direct interaction
between immune cells in a paracrine and/or autocrine fashion
independent of sensory nerves [4,8]. The tachykinins can
modulate the immune response and SP has been shown to
regulate production of a number of cytokines including IL-1, IL-6,
IL-8 and TNFa to mediate inflammatory and cell proliferative
responses [9,10]. In addition to the classical peptides SP and NKA,
the recently discovered peptides such as hemokinin 1 and the
endokinins have been found in non-neuronal cells/tissues such as
pulmonary and cardiovascular tissue, articular cartilage and cells
of the immune system [11,12] and they have high affinity SP
receptors, NK-1
R [13] adding a further layer of complexity to the
tachykininfunctioninhostdefence.Itisthereforeimportanttodefine
the temporal and spatial regulation of the tachykinins and
hemokininsintheperipheryinresponsetochallenge.Thegeneration
of transgenic mice that co express the PPT-A gene with the LacZ
marker gene [14,15] has allowed us to explore the expression and
function of the PPT-A gene in this manner in the lung.
The tachykinins have been extensively implicated in the
initiation and progression of lung disease processes such as
bronchitis and asthma [16–19]. It has been suggested that SP,
NKA and their respective high affinity receptors NK-1
R and NK-
2
R are important. These peptides would have different functions in
the lung as they contract smooth muscle cells mainly by interaction
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R, while an increase in vascular permeability
and pro-inflammatory effects are mediated by SP on the NK-1
R
[16]. In such a manner tachykinins are potent contractors of
airways producing a dose-related bronchoconstriction when
administered by means of inhalation to asthmatic subjects [20].
Similarly a number of studies have shown that viruses (e.g.
respiratory syncytial virus and murine gammaherpesvirus, MHV-
68) can induce SP and neurogenic inflammation, particularly in
lungs in the context of a respiratory challenge [21–23]. In
addition, NK1 is upregulated in lymphocytes (especially T cells) in
the lung in response to viral infection in the lung [24] and
antibody to SP decreases inflammatory responses to pulmonary
viral infection [25]. This indicates a primary role for SP in the lung
in the response to respiratory viral infection. These actions of the
tachykinins in response to virus infection are similar to bronchitis
and asthma [21,22,26,27]. We demonstrate here that induction of
the PPT-A gene and the subsequent synthesis of SP in specific non
neuronal cell populations in the lung are an early response to
MHV-68 infection. This further supports a model where induction
is initiated by interaction of the cell with the virus particle.
Results
PPT-A gene expression is induced in airways following
MHV-68 infection
Tachykinins, including SP are found in increased levels in the
lung after respiratory infection. However, the exact source of the
tachykinin peptides has never been precisely identified. To
determine if tachykinin gene expression was induced locally in
airways in response to infection with a respiratory virus, we
initially utilised transgenic mice (143-YAChPPT-ALacZ) that had
been engineered to co-ordinately express a transgenic, human
copy of PPT-A (htPPT-A) and the LacZ reporter gene. The product
of the latter can readily be rapidly and easily detected in tissues by
a simple staining method. Thus, LacZ staining in these mice is a
surrogate marker for htPPT-A gene expression. 143-YAChPPT-
ALacZ mice were infected intranasally with murine gammaher-
pesvirus 68 (MHV-68) and groups of 3 mice were euthanized at 1,
3 and 7 days post-infection. Lungs, including trachea and lymph
nodes were removed and stained whole using X-gal as substrate.
Mock-infected mice served as controls.
The results (Fig. 1) showed that there was no detectable LacZ
staining in mock-infected mice at any time-point (Panel A).
However, as early as day 1 p.i., LacZ staining was observed in
airways of lungs from infected mice (Panel B). This staining
persisted through day 7 p.i.. htPPT-A gene expression in the
context of the well characterised transgenic model was therefore
induced locally in airways after MHV-68 infection.
Epithelial cells and macrophages in airways are induced
to express PPT-A during infection
To identify precisely the cell types induced to express PPT-A in
airways, groups of 143-YAChPPT-ALacZ mice were infected with
MHV-68 as above and euthanized at 1, 2 , 3 and 7 days p.i.
Mock-infected mice served as controls. Lung tissue including
trachea and lymph nodes was snap-frozen and cryosections
prepared. Sections were stained for the presence of LacZ and
examined by light microscopy. HE-stained sections served to assess
any morphological alterations.
The results (Fig. 2) showed LacZ staining in occasional alveolar
and bronchial epithelial cells in mock-infected mice (Panel A). As
early as day 1 p.i. with MHV-68 there was a general increase in the
numbers of LacZ-positive tracheal, bronchial and alveolar epithelial
cells. Trachea and bronchi often exhibited patches of positive
epithelial cells (Panel B). The staining in the lung parenchyma was
also patchy. Some alveoli contained single, scattered positive
epithelial cells, mainly with the morphology of type II pneumocytes,
others were entirely positive (Panels C, D). Occasionally, positive
desquamated alveolar epithelial cells/macrophages as well as
positive syncytial cells were seen in alveolar lumina (Panel D). On
days 2, 3 and 7 p.i., staining was similar, but appeared gradually less
extensive than on day 1 p.i. This was obvious in a lower number of
alveoli exhibiting positive cells. However, entire alveoli with positive
cells were found at each time point.
These results indicate that a small number of cells in the
respiratory tract constitutively express the htPPT-A transgene in
uninfected mice. However, a large number of airway epithelial
cells and macrophages are rapidly induced to express the htPPT-A
gene after respiratory challenge with MHV-68.
Substance P peptide expression is induced along with
PPT-A gene expression
To confirm that SP peptide was being produced along with
PPT-A gene expression, frozen sections consecutive to those used
for LacZ staining and sections prepared from paraformaldehyde
(PFA)-fixed, paraffin wax-embedded tissue from the same mice
analyzed above were immunohistologically stained for SP. The
results are shown in Fig. 3.
In mock-infected mice, SP expression was observed in
occasional alveolar and bronchial epithelial cells (Panel A, B).
Some positive alveolar epithelial cells had the morphology of type
II pneumocytes. Desquamated alveolar macrophages, if present,
were intensely positive.
On day 1 p.i., mice exhibited numerous individual and patches
of tracheal and bronchial epithelial cells which stained positive for
SP. In alveoli, positive epithelial cells were seen, some of which
had the morphology of type II pneumocytes (Panels C, D). Positive
desquamated epithelial cells and macrophages were occasionally
observed within alveolar lumina. On days 2, 3 and 7 p.i., airway
epithelial expression patterns were similar to those seen at day 1
p.i., with similar numbers of positive cells on days 2 and 3, but
overall lower numbers of positive cells on day 7 p.i.
No reaction was seen in a negative control where the primary
antibody was replaced with buffer (Panel E).
Figure 1. LacZ expression in lungs from infected and uninfect-
ed 143-YAChPPT-ALacZ mice. Groups of 143-YAChPPT-ALacZ mice
were infected or mock-infected with MHV-68 and euthanized at various
time-points post-infection. Micrographs show whole lung blocks from
mock-infected (Panel A) and infected (Panel B) mice at 1 day p.i. stained
for the presence of the LacZ marker (blue). Staining for LacZ is observed
within trachea and bronchi (arrows) of the infected mouse only
doi:10.1371/journal.pone.0001673.g001
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htPPT-A gene expression as both are detected in similar cells in
trachea, bronchi and alveoli, and with a similar focal distribution.
Induction of SP expression occurs in non-transgenic mice
Although previous studies have shown that the pattern of LacZ
staining corresponds to known endogenous (non-transgenic) PPT-
A gene expression in mice, we were concerned that there might be
differences between expression in the 143-YAChPPT-ALacZ mice
and non-transgenic mice. We therefore repeated the above
experiments using BALB/c mice and stained PFA-fixed, paraffin
wax-embedded tissue sections for SP expression.
The results (Fig. 3 F–H) showed that the pattern of SP staining
in BALB/c mice was comparable to that seen in 143-YAChPPT-
ALacZ mice. Thus, SP expression was observed in occasional,
scattered bronchiolar and alveolar epithelial cells in uninfected
mice (Panel F). In infected mice, there were numerous positive
tracheal, bronchial and alveolar epithelial cells and alveolar
macrophages (Panels G, H). The numbers of positive cells
appeared again greatest at days 1–3 p.i..
Thus, the induction of SP expression in airways after infection
was also validated for the endogenous murine PPT-A gene.
Foci of PPT-A/SP expression correspond with areas of
viral infection
During the acute phase of infection, MHV-68 predominantly
infects airway epithelial cells, in particular alveolar epithelial cells.
To determine whether the foci of viral infection corresponded to
the distribution of SP expression after infection, serial sections
were cut from the lung tissue of the infected 143-YAChPPT-
ALacZ and BALB/c mice and stained for either LacZ/SP or
MHV-68 antigen. Due to the kinetics of MHV-68 replication and
spread in the host, viral antigen was not detected until day 3 p.i.
when scattered individual alveolar epithelial cells were positive
(Fig. 4A). Viral antigen expression was more abundantly observed
on day 7 p.i. (Fig. 4B). However, LacZ staining and MHV-68
antigen were observed in a similar alveolar epithelial location
(Fig. 4A, B). No reaction was observed in a negative control where
primary antibody was replaced by buffer (Panel C).
Discussion
Sensory C-type fibres are thought to provide the predominant
source of tachykinins, including SP, in the lung and have a role in
the pathophysiological response to challenge in the lungs which
have been well documented. However, our manuscript provides
strong evidence that as a response to infectious challenge,
tachykinin production in the lung is initiated locally in non-
neuronal cells. This local tachykinin release may then contribute
to the inititation of a cascade that includes the host immune
response and the neurogenic inflammatory response.
To examine whether SP was being produced in situ in the lung
as opposed to being released from nerve terminals, animals from a
previously established transgenic mouse line expressing human
PPT-A co-ordinately with the LacZ marker gene were used for the
viral infections. In this transgenic line (143-YAChPPT-ALacZ), a
YAC (yeast artificial chromosome) containing the human PPT-A
locus had been isolated from a human cDNA library and an
internal ribosomal entry site (IRES)-LacZ marker gene cassette
had been cloned into the non-coding exon 7 through homologous
recombination. LacZ expression is therefore a surrogate marker
for PPT-A gene transcription and positive cells can be easily
Figure 2. Histological detection of PPT-A expression in respiratory tissue. Groups of 143-YAChPPT-ALacZ mice were infected or mock-
infected with MHV-68 and euthanized at various time-points post-infection. Micrographs show trachea and lung tissue sections stained for the
presence of the LacZ marker (blue; frozen sections). A. Mock-infected 143-YAChPPT-ALacZ mouse. LacZ expression is observed in individual bronchial
(arrow) and alveolar (arrowheads) epithelial cells. C: bronchial cartilage. Bar=40 mm. B. 143-YAChPPT-ALacZ mouse, day 1 post infection. A large
patch of tracheal epithelial cells exhibit LacZ staining (arrows). Bar=20 mm. C. 143-YAChPPT-ALacZ mouse, day 1 post infection. Several alveoli exhibit
LacZ staining of all epithelial cells (arrows), in others only occasional cells, often with the morphology of type II alveolar epithelial cells (arrowhead)
are positive. Bar=40 mm. D. 143-YAChPPT-ALacZ mouse, day 1 post infection. Higher magnification of Panel C, showing staining for LacZ in
numerous alveolar epithelial cells. A positive syncytial cell is also seen (arrow). Bar=10 mm.
doi:10.1371/journal.pone.0001673.g002
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analyses of the transgenic lines produced showed that the LacZ
and PPT-A genes were being correctly anatomically expressed in
the central and peripheral nervous system [15]. Although the
respiratory tract has an extensive network of peptidergic
innervation, in this study, epithelial cells lining the air passages
of 143-YAChPPT-ALacZ mice were found to be transcribing
htPPT-A mRNA in response to viral infection, as shown by the
presence of blue staining in the airways corresponding to
expression of the marker gene LacZ. Given that these animals
produced the expected patterns of the endogenous PPT-A gene in
the rodent nervous system we have no reason to believe that the
Figure 3. Immunohistological detection of SP expression in respiratory tissue. Groups of 143-YAChPPT-ALacZ mice (Panels A-E) and BALB/c
mice (Panels F-H) were infected with MHV-68 or mock-infected and euthanized at various time-points post-infection. Micrographs show airway and lung
tissue sections stained for the presence of SP (brown; frozen or paraffin-embedded tissue sections, peroxidase anti-peroxidase method, anti-SP,
Papanicolaou’s haematoxylin counterstain). A, B. Mock-infected 143-YAChPPT-ALacZ mouse. SP expression is seen as very weak cytoplasmic staining of
occasional bronchial epithelial cells (arrow) or alveolar epithelial cells (arrowheads). Bars=20 mm. C, D. 143-YAChPPT-ALacZ mouse, day 1 post infection.
Numerous alveolar epithelial cells stain positive for SP (arrows); some of these can be identified as type II pneumocytes (arrowheads). C: PFA-fixed and
paraffin wax-embedded tissue section, D: Frozen section. Bars=20 mm. E. 143-YAChPPT-ALacZ mouse, day 1 post infection. No reaction is seen in the
negative control section, where the primary antibody was replaced by tris-buffered saline. Bar=20 mm. F. Mock-infected BALB/c mouse. SP expression is
seen as cytoplasmic staining of occasional alveolar epithelial cells (arrowheads). Bar=20 mm. G. BALB/c mouse, day 2 post infection. Numerous bronchial
respiratory epithelial cells exhibit moderate to intense staining for SP (arrows). Bar=20 mm. H. BALB/c mouse, day 1 post infection. Numerous alveolar
epithelial cells stain positive for SP; many of these can be identified as type II pneumocytes (arrowheads). Bar=20 mm.
doi:10.1371/journal.pone.0001673.g003
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lung. However,weconfirmed synthesis ofSPproteininthesecells by
immunostaining for SP in both transgenic and non-transgenic
(BALB/c) animals. In the non-transgenic animals, the SP produced
can only be synthesised bythe mouse gene. Further, we saw a similar
pattern of SP-specific staining in the two mouse strains, indicating
that the induction is not a strain specific response.
We have shown production of SP peptide by airway epithelial
cells. PPT-A precursor protein needs to be processed into its
constituent peptides by neutral endopeptidase (NEP; EC
3.4.24.11, also called CD10) before it becomes active. One
concern therefore was that the nascent tachykinin peptide
produced by epithelial cells might not be processed into active
protein. However, it has previously been shown that NEP/CD10
is constitutively expressed by alveolar and airway epithelial cells in
vivo [28]. This indicates that the PPT-A precursor observed in
airway epithelia will be processed into active peptides and be able
to exert their effects locally.
The htPPT-A transgenic model which co-ordinately expresses
the LacZ marker allowed us not only to determine which cells
were expressing PPT-A in response to challenge but also permitted
us to determine the temporal cascade of expression. Expression of
LacZ (and hence htPPT-A) in airway epithelial cells was initiated at
a very early time after infection (24 h p.i.) and persisted, through
7 days p.i.. This is unusual as the induction of most pro-
inflammatory and immunomodulatory mediators (e.g. IFN-c, IL-
6, IL-10, RANTES, MIP-1a, MIP-1b, IP-10) in the lungs of mice
in viral respiratory challenge models does not occur until at least
3 days p.i., peaking around 6 through 10 days p.i. [29–32]. The
timing of the htPPT-A and SP induction in airway epithelia is
clearly earlier than this and more akin to that of IFN-a, which is
rapidly induced in the lung during the first few days after infection
[33]. The timing of SP induction is extremely significant and
indicates that locally-produced SP is likely to be involved in the
initiation of the host inflammatory and immune response in the
lung, rather than being downstream of the induction of other
inflammatory mediators. The effects of locally-produced SP are
likely to involve paracrine and autocrine loops as human bronchial
epithelial cell lines also respond to SP with a rise in synthesis and
release of inflammatory cytokines in a receptor mediated fashion
[34]. This is especially important for respiratory infection as the
epithelial cells lining the lumen are the first to encounter and
respond to invasion by pathogens.
An important role for tachykinins released from the non
neuronal cells to infection has not only been demonstrated in our
previous work [23] but also for respiratory syncitial virus (RSV).
Consistent with this RSV, a respiratory viral infection similar to
MHV-68, initiates a lower inflammatory response if the pulmo-
nary neuronal SP release is inhibited [21] analogous in part to the
response we had previously observed with MHV-68 [23]. In other
organs a similar role for tachykinins synthesised in non neuronal
cells has also been postulated. In murine Schistosoma mansoni
infection, for example, ova embed in the liver and induce a local
Th2-type granulomatous inflammatory response. SP is necessary
for a normal immune response to this pathogen as shown by
infection of NK1-R knock out mice [35]. We have also
demonstrated that inappropriate expression of PPT-A and
expression of SP in human chondrocytes is correlated with the
progression of arthritis and the control of IL-4 expression in that
model [36]. Together this set of data suggests stimulus inducible
expression of the tachykinins in non neuronal cells may be a
common response mechanism not only in the lung but in a variety
of other cells.
An important and early role for tachykinins in the induction of
inflammation and the immune response suggests that the selective
use of tachykinin agonists or antagonists could be of use in
Figure 4. Immunohistological detection of MHV-68 antigen in respiratory tissue. Groups of BALB/c mice were infected with MHV-68 and
euthanized at various time-points post-infection. Micrographs show airway and lung tissue sections stained for the presence of MHV-68 antigen
((brown; paraffin-embedded tissue sections, peroxidase anti-peroxidase method, anti-MHV-68, Papanicolaou’s haematoxylin counterstain). A. BALB/c
mouse, day 3 post infection. MHV-68 antigen is expressed by an individual type II alveolar epithelial cells (arrow). Bar=20 mm. B. BALB/c mouse, day 7
post infection. MHV-68 antigen is expressed by several individual and small groups of alveolar epithelial cells (arrows). Bar=20 mm. C. BALB/c mouse,
day 7 post infection. No reaction is seen in the negative control section, where the primary antibody was replaced by tris-buffered saline. Bar=20 mm.
doi:10.1371/journal.pone.0001673.g004
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response to pathogens or vaccines to improve clearance of a
persistent virus or response to vaccination. In contrast, tachykinin
antagonists might be of use where immunopathological processes
resulting from infection cause morbidity or mortality (e.g. RSV
infection in infants).
Materials and Methods
Infection of Mice
All animal work was performed under UK Home Office Project
Licence number 40/2483 and Personal Licence number 60/6501.
BALB/c mice were purchased from Bantin and Kingman (Hull,
UK). The transgenic mouse line termed 143-YAChPPT-ALacZ
containing the human Preprotachykinin-A (PPT-A) gene co-
expressing the b-galactosidase (LacZ) reporter gene was produced
by using a yeast artificial chromosome construct [14]. The
expression of the human gene can be followed in vivo by LacZ
staining.
Groups of animals were anesthetized with isoflurane and
inoculated with 4610
5 PFU MHV-68 in 40 ml of sterile phosphate
buffered saline (PBS). At various times post infection (p.i.), animals
were euthanized and entire lungs with trachea and lymph nodes
were harvested. Four mice from each group were euthanized at
day 1 (24 h) p.i. and 3 animals from each group were euthanized
at days 2, 3 and 7 p.i., respectively. Uninfected mice from each
group served as controls.
Detection of LacZ in entire lungs
Entire lungs with trachea and lymph nodes were rinsed and
placed in solution A (1M PBS containing 1M MgCl2) for 30 mins
at room temperature. They were then rinsed with solution B (1M
PBS containing 1M MgCl2, 0.01% sodium deoxycholic acid,
0.02% IGEPAL) and placed in solution B for 5 mins at room
temperature. Tissues were then stained by incubation for 20–24h
at 37uC with staining solution (Xgal (1mg/ml) dissolved in 1M
PBS containing 1M MgCl2, 0.01% sodium deoxycholic acid,
0.02% IGEPAL, 5mM potassium ferricyanide, 5mM potassium
ferrocyanide). Staining solution was then removed and replaced
with 1M PBS until photographs were taken on a dissecting
microscope (not longer than two days after staining).
Detection of LacZ in tissue sections
Lung tissue including trachea and bronchial lymph nodes were
taken from 143-YAChPPT-ALacZ mice and snap-frozen at
280uC after embedding in Tissue TekH (O.C.T.
TM compound;
Sakura, Zoeterwoude, The Netherlands). Sections (5–6 mm) were
prepared on a cryotome and were stained with haematoxylin-eosin
(HE), were used for the detection of PPT-A transcription by the
staning for LacZ as above or were used for the immunohistological
detection of substance P and MHV-68 antigen.
Histology and Immunohistology
Additional lung samples were fixed in 4% buffered paraformal-
dehyde (PFA; pH 7.4) and were routinely embedded into paraffin
wax. Sections (3–5 mm) were stained with HE or used for the
immunohistological detection of SP and MHV-68 antigen.
For the detection of SP and MHV-68 antigen, the peroxidase
anti-peroxidase (PAP) method was used. Briefly, paraffin-embed-
ded sections were dewaxed in xylene and rehydrated through
graded alcohol while Tissue TekH-embedded frozen sections were
rinsed in tris buffered saline (TBS; pH 7.6). After inactivation of
endogenous peroxidase with 0.5% H2O2 in methanol, antigen
retrieval by incubation with 10 mM citrate buffer (pH 6.0) at 97uC
was performed on the PFA-fixed tissue sections. Slides were then
incubated for 15–18 h at 4uC with the primary antibodies (rabbit
anti-SP; BP823, DPC Biermann GmbH, Hiddenhausen, Ger-
many; diluted 1:100; rabbit anti-MHV-68, diluted 1:2000) in TBS
with 20% swine serum. Binding was demonstrated by the PAP
method and visualisation with diaminobenzidin tetrahydrochlor-
ide. Consecutive negative control sections where the primary
antibody was replaced by TBS were prepared for each section
stained for SP or MHV-68 antigen.
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